Skip to main content

Table 3 Participants reporting symptoms at least once between day 0 and day 13 by study site

From: The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial

Country

Site

Patients

Vomiting

Diarrhoea

Anorexia

Nausea

Abdominal pain

Dizziness

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Afghanistan

Jalalabad

311

37 (11.9%)

15 (4.8%)

99 (31.8%)

73 (23.5%)

62 (19.9%)

47 (15.1%)

Laghman

120

11 (9.2%)

5 (4.2%)

47 (39.2%)

27 (22.5%)

11 (9.2%)

1 (0.8%)

Ethiopia

Arba Minch

371

200 (53.9%)

89 (24.0%)

361 (97.3%)

284 (76.5%)

235 (63.3%)

279 (75.2%)

Metehara

208

51 (24.5%)

11 (5.3%)

109 (52.4%)

96 (46.2%)

36 (17.3%)

4 (1.9%)

Indonesia

Hanura

575

289 (50.3%)

53 (9.2%)

407 (70.8%)

426 (74.1%)

334 (58.1%)

194 (33.7%)

Tanjung Leidong

425

212 (49.9%)

15 (3.5%)

378 (88.9%)

365 (85.9%)

354 (83.3%)

112 (26.4%)

Vietnam

Dak O & Bu Gia Map

219

20 (9.1%)

15 (6.8%)

15 (6.8%)

9 (4.1%)

33 (15.1%)

4 (1.8%)

Krong Pa

106

4 (3.8%)

2 (1.9%)

5 (4.7%)

4 (3.8%)

7 (6.6%)

0 (0%)

Total

 

2,335

824 (35.3%)

205 (8.8%)

1,421 (60.9%)

1,284 (55.0%)

1,072 (45.9%)

641 (27.5%)